Sanolla Sanolla נייד

Sanolla's smart diagnostic solutions for physicians and patients support early assessment and monitoring of cardiopulmonary conditions such as congestive heart failure, pneumonia, asthma, chronic obstructive pulmonary disease, COVID-19 and more. Based on AI-powered detection and analysis of previously inaccessible body infrasounds and other important vital signs (ECG, heart rate, oxygen level, body temperature and respiratory cycle), Sanolla's products can provide immediate and accurate assessment, reducing unnecessary in-clinic visits, saving time and money, and lower the risk of infection.

Type Stocks
Category Medical Device
Minimum Investment $25,000

The RPM industry is growing rapidly

Sanolla is part of the growing industry of remote patient monitoring (RPM). According to a report by Grand View Research, the global market cap of RPM systems was estimated at $956 million in 2020 and is expected to scale at an annual growth rate (CAGR) of 19.7% from 2021 to 2028.


The Team Leading Sanolla

The company was founded and is led by Dr. Doron Adler, a serial entrepreneur with an impressive track record in establishing successful med-tech companies. Prior to founding Sanolla, Dr. Adler was the founder and CEO of CByond for 15 years until it was acquired by Olympus for $2.1B.

Next to Dr. Adler, the Co-Founder & COO of Sanolla is David Linhart, an experienced manager specializing in all aspects of operational excellence. Prior to co-founding Sanolla, David was Director of Operations for Olympus Medical, which acquired CByond where he held the role of COO.  He spent 14 years in various management roles within A.R. Telecom systems and worked with the Israeli Ministry of Defense.

The Chief Medical Officer of the company is Prof. Shmuel Banai, one of Israel’s leading Cardiologists and a well-known researcher. Professor Banai leads a productive career as both the Director of Cardiology and the Head of Interventional Cardiology at Tel Aviv Souraski Medical Center.

Sanolla’s Solutions

Sanolla has 2 groundbreaking developments in the fields of cardiology and respiratory medicine, each of which meets a broad global need:

PyXy – Home monitoring AI and infrasound-based device for the early detection of exacerbations in the chronic cardiopulmonary diseases of heart failure, COPD, and asthma. These chronic diseases create a massive burden on healthcare systems around world. On their own, each of these diseases costs between $15B-$20B in exacerbation and hospitalizations. 

PyXy, because of its infrasound capabilities is able to detect exacerbations at the earliest stages. When an exacerbation is detected early enough, it can be resolved through minimal intervention such as taking medicines.

VoqX – Smart stethoscope with infrasound and AI for improving the diagnostic decision-making of clinicians. Physicians are faced with diagnostics dilemmas each day. Is the person with a cough and a fever suffering from pneumonia or bronchitis? The course of treatment for both of these diseases is quite different. With a standard stethoscope, the physicians’ accuracy in diagnosing pneumonia is only 55% while with the VoqX and its infrasound, the detection accuracy exceeds 90%. Similarly, VoqX will help physicians diagnose myocardial infarction (chest pains due to a heart attack) and detect heart valve problems like aortic stenosis, which affects 20% of senior citizens, but is not diagnosed for 80% of them. Delayed diagnosis can be fatal in all the cases mentioned above. VoqX with its unmatched auscultation sounds clarity and infrasound-based AI decision support empowers clinicians to diagnose correctly and as early as possible.

Status of the products

The company has 17 patents, 8 of which have already been granted and registered, and another 9 are pending.

PyXy – Undergoing the final stage of product development. Regulatory clearance is expected in the summer of 2022 with a commercial launch in September 2022.

VoqX – Production line is now scaling. AMAR regulatory clearance was received for sales in Israel. FDA clearance expected in Q1/2022. Commercial terms negotiated with major worldwide distribution and manufacturing entities. Clinical studies are completed for AI and validation is taking place now.

Investors and grants

Sanolla received a €5 million grant from the EU Horizon 2020 initiative – this is a particularly valuable grant and the company was rated by analysts as having the highest possible score on all the parameters on which it was tested. In addition, the company has received grants from the Israeli Innovation Authority.

Sanolla enjoys support and funding from “Next Leap Venture” Fund and from groups of Israeli angel investors who believe in the company’s potential for success.

Competitors Landscape

Telemedicine Auscultation Devices of companies like TytoCare, Stethlo, Nanogon, and CliniCloud use the audible spectrum only and have no disease classification using AI. In addition, these devices require a physician to be online with the patient. This is not sustainable for daily home monitoring as the burden on the healthcare system would be excessive.

 Digital Stethoscope Devices (Competition to VoqX) provide amplification of the narrow-band audible information only. Some have ambient noise cancellation using fixed filters that are inferior to the dynamic noise cancellation used in the VoqX. No AI is implemented. Essentially, these devices are targeted for clinicians requiring sound amplification. Competitors in this market include ADC, Littman, ThinkLab, Stethee, and eKuore.

AI-Powered Digital Auscultation Devices include the features of the digital stethoscope devices described above but apply AI algorithms only to the narrow-band audible information. Competitors in the market include Coala, EKO, and StethoMe. The accuracy of narrow-band AI disease classification is inherently inferior since it is based on less data than Sanolla’s full-spectrum solutions. These competitors are more focused on either cardiac auscultation or pulmonary while Sanolla provides both cardiac and pulmonary auscultation along with AI.

Opportunity and market size

The markets in which Sanolla operates are massive and include end-users suffering from chronic diseases who will purchase the PyXy and use it in their private home. This market is estimated at $480 billion calculated from a combination of the device’s acquisition costs and SaaS subscriptions. Insurance companies and health funds are expected to encourage these purchases as they save capital for health systems and insurance coverage.

VoqX is designed for use in any clinic with an emphasis on hospitals, ambulances, and intensive care. The total market is estimated at $18 billion and consists of a combination of pre-device costs and SaaS subscriptions. The company can already see high demand and interest in the product from these huge customers including signing terms documents.

We Are Here For You!